Need Help?
No Article Versions Notes Found
Cite
Schlander, M.; Garattini, S.; Kolominsky-Rabas, P.; Nord, E.; Persson, U.; Postma, M.; Richardson, J.; Simoens, S.; de Solà -Morales, O.; Tolley, K.; et al. Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement. J. Mark. Access Health Policy 2016, 4, 33039. https://doi.org/10.3402/jmahp.v4.33039
Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, Richardson J, Simoens S, de Solà -Morales O, Tolley K, et al. Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement. Journal of Market Access & Health Policy. 2016; 4(1):33039. https://doi.org/10.3402/jmahp.v4.33039
Chicago/Turabian StyleSchlander, Michael, Silvio Garattini, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol de Solà -Morales, Keith Tolley, and et al. 2016. "Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement" Journal of Market Access & Health Policy 4, no. 1: 33039. https://doi.org/10.3402/jmahp.v4.33039
APA StyleSchlander, M., Garattini, S., Kolominsky-Rabas, P., Nord, E., Persson, U., Postma, M., Richardson, J., Simoens, S., de Solà -Morales, O., Tolley, K., & Toumi, M. (2016). Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement. Journal of Market Access & Health Policy, 4(1), 33039. https://doi.org/10.3402/jmahp.v4.33039
